Contextlogic Inc Cl A (LOGC)

Mar 12, 2025, 8:30 PM EDT - 6 weeks ago

ContextLogic Inc. (WISH) Q4 2024 Earnings Conference Call Transcript

Mar 12, 2025, 4:00 PM EDT - 6 weeks ago

ContextLogic Inc. Reports Fourth-Quarter and Fiscal Year 2024 Financial Results

Mar 10, 2025, 8:00 AM EDT - 6 weeks ago

ContextLogic to Announce Fourth Quarter and Full Year 2024 Results and Provide Strategic Update on March 12, 2025

Nov 7, 2024, 4:10 PM EST - 6 months ago

ContextLogic Inc. Reports Third-Quarter 2024 Financial Results

Aug 8, 2024, 4:15 PM EDT - 9 months ago

ContextLogic Inc. Reports Second-Quarter Financial Results

Nov 16, 2022, 8:23 AM EST - 2 years ago

Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics

Nov 14, 2022, 8:00 AM EST - 2 years ago

LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Oct 18, 2022, 7:30 PM EDT - 2 years ago

LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC

Oct 3, 2022, 9:56 AM EDT - 2 years ago

LogicBio's stock skyrockets after buyout bid for a 667% premium

AZN

Oct 3, 2022, 8:25 AM EDT - 2 years ago

AstraZeneca pays 660% premium for gene therapy firm LogicBio

AZN

Oct 3, 2022, 7:15 AM EDT - 2 years ago

Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine

Sep 21, 2022, 8:30 AM EDT - 2 years ago

LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE

Aug 15, 2022, 7:05 AM EDT - 2 years ago

LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

May 17, 2022, 8:30 AM EDT - 3 years ago

LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference

May 16, 2022, 8:30 AM EDT - 3 years ago

LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates

May 11, 2022, 8:30 AM EDT - 3 years ago

LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting

May 9, 2022, 10:26 AM EDT - 3 years ago

Why LogicBio Therapeutics Shares Are Popping Off Today

May 9, 2022, 8:50 AM EDT - 3 years ago

LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatric Trial

May 9, 2022, 8:00 AM EDT - 3 years ago

LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia

Mar 23, 2022, 4:30 PM EDT - 3 years ago

LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference

Mar 8, 2022, 4:05 PM EST - 3 years ago

LogicBio Therapeutics to Present at Barclays Global Healthcare Conference

Mar 4, 2022, 4:05 PM EST - 3 years ago

LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates

Feb 2, 2022, 12:34 PM EST - 3 years ago

Why Did LogicBio Therapeutics Shares Plunge To 52-Week Low Today?

Feb 2, 2022, 6:00 AM EST - 3 years ago

LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program

Jan 4, 2022, 8:00 AM EST - 3 years ago

LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

Dec 22, 2021, 8:00 AM EST - 3 years ago

LogicBio Therapeutics Provides Business Updates

Nov 15, 2021, 7:00 AM EST - 3 years ago

LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones

Nov 11, 2021, 4:05 PM EST - 3 years ago

LogicBio Therapeutics to Participate in Upcoming Investor Conferences

Oct 21, 2021, 8:00 AM EDT - 3 years ago

LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using GeneRide™ Genome Editing Technology

Oct 18, 2021, 8:00 AM EDT - 3 years ago

LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children

Oct 12, 2021, 4:05 PM EDT - 3 years ago

LogicBio Therapeutics to Present New GeneRide™ Data at the European Society of Gene and Cell Therapy Virtual Congress 2021

Sep 24, 2021, 4:05 PM EDT - 3 years ago

LogicBio Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Sep 10, 2021, 8:00 AM EDT - 3 years ago

LogicBio Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Aug 9, 2021, 8:00 AM EDT - 4 years ago

LogicBio Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones

Jul 8, 2021, 7:00 AM EDT - 4 years ago

LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021

Jun 2, 2021, 7:00 AM EDT - 4 years ago

LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia

May 19, 2021, 7:00 AM EDT - 4 years ago

LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments

May 10, 2021, 7:30 AM EDT - 4 years ago

LogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business Update

May 10, 2021, 7:05 AM EDT - 4 years ago

LogicBio Therapeutics Strengthens Management Team with Key Appointments

May 4, 2021, 8:00 AM EDT - 4 years ago

LogicBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 3, 2021, 5:29 PM EDT - 4 years ago

Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal

BPMC IMAB JNJ LEGN MIRM

May 3, 2021, 4:30 PM EDT - 4 years ago

LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia

Apr 27, 2021, 9:51 AM EDT - 4 years ago

LogicBio Therapeutics, CANbridge Ink Partnership For Development Of Gene Therapy Candidates

Apr 27, 2021, 8:00 AM EDT - 4 years ago

CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery and Editing Platforms

Apr 27, 2021, 7:00 AM EDT - 4 years ago

LogicBio Therapeutics Announces Clinical and Corporate Updates

Apr 27, 2021, 7:00 AM EDT - 4 years ago

LogicBio Therapeutics Announces Research Collaboration with Daiichi Sankyo

Mar 30, 2021, 4:30 PM EDT - 4 years ago

LogicBio Therapeutics to Present at 2021 Redburn Gene Therapy Summit